[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-aging":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,84,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641516","evaluation-of-the-efficacy-and-tolerability-of-the-led-mask-with-or-without-the-serum-formula-on-the-signs-of-facial-photodamage--100641516",false,"NCT07661004","Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage .","Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage","Inclusion Criteria:\n\n1. Female subjects aged between 35-60y.o\n2. Presenting all skin types\n3. Presenting all phototype according to Fitzpatrick Classification\n4. Sensitive skin (50%) - declarative\n5. Daily user of SPF30 or 50+ for at least 30 days\n6. User or not of LED masks (collected data)\n7. Mask adapted to the shape of the face\n8. Having mild to moderate scores (as indicated) for the items parameters\n9. Subjects willing not to change their face\u002Feyes make-up removal products and habits, and shower habits (e.g. shampoo, shower gel), and make-up products (eyes and mouth) throughout the course of the study.\n10. Subjects willing to use the investigational devices and\u002For products on the face throughout the course of the study period\n11. Subjects taking an effective oral contraception or other methods of contraception for the duration of the study\n12. Written Informed Consent Form to participate in the study\n13. illingness and ability to comply with protocol requirements\n\nExclusion Criteria:\n\n1. Subjects having allergy or sensitivity to LED Light\n2. Subjects having at risk of epilepsy\n3. subject who may have headaches\n4. Subjects having participated in the clinical study using anti-aging formula on the face within at least 3 months preceding the baseline visit\n5. Subjects having used any cosmetic products with exfoliating or astringing allegation on the face within at least 4 weeks preceding the baseline visit\n6. Subject with arterial circulatory disorders in the treated area,\n7. Subjects with sensitivity troubles and pain perception impairment, facial paralysis,\n8. Subjects with degenerative and vascular retinal disease,\n9. Subjects with known problems of scarring or wound healing,\n10. History of photosensitivity or photo allergy\n11. History of chronic viral infections (herpes simplex, ZONA…) and last outbreak within 12 months preceding the baseline visit\n12. Subject having an underlying dermatological disease or conditions on the face, which in the investigator's opinion, could interfere with study evaluation\n13. Subjects with a melanoma history in the family (parents or grandparents)\n14. Subjects undergone the radiotherapy in the treated areas,\n15. Subject having excessive moles, excessive pigmented spots, tattoos, scars, irritated skin, etc. at the test area that could influence the investigation\n16. Subject with a history of surgery to the treatment concerned areas within 6 months preceding the baseline visit\n17. Subject reports (or plans to) sunbath or overexpose to UV-light (mountains sports, phototherapy, tanning salon use…) for aesthetic or therapeutic reason one month before the study start (or during the study).\n18. Subject having modified their cosmetic habits (moisturizing skin care, cleansers, make-up removers, make-up, shower products, shampoo…) during the 2 weeks before baseline visit.\n19. Subject uses or has used any of the medications or topical treatments\u002Fskincare products\u002Fprocedure below without relevant wash-out period before the baseline visit (or is unwilling or unable to accept to follow the wash-out period below during the study)\n\n    \\-","FEMALE","35 Years","60 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","Main objective : To evaluate the anti-aging effectiveness of the LED mask alone on at least one studied anti-aging parameters (including some targeted wrinkles) after 3 months versus baseline\n\nSecondary objectives:\n\n* Anti-aging clinical score (radiance, skin tone, fine line, ptose, plumpness, ..)\n* Evaluate the consumer perception (self-evaluation)\n* Tolerance\n* Standardized pictures (all light) and pictures analysis\n* Comparison of effectiveness between the 2 groups (with and without formula",[27,28],"Photodamage of the Face","Anti Aging",[30,31,32,33,34],"WRINKLES","SAFETY","EFFICACY","MASK LED","CONSUMER PERCEPTION","NOT_YET_RECRUITING","2026-06-16",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":21},"2026-09-01",{"date":43,"type":21},"2027-04-01",{"name":45,"class":46},"L'Oreal","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":47},"100624304","ivs-1-probiotic-intervention-targeting-biological-aging-in-midlife-adults-100624304","NCT07407894","iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults","VITAL-Age Trial (iVS-1 Investigation for Targeting Aging and Longevity)","VITAL","Inclusion Criteria:\n\n* Aged 40-75 years.\n* BMI: 20-34.9 kg\u002Fm².\n* Able and willing to sign informed consent and participate for the study duration.\n\nExclusion Criteria:\n\n* Chronic disease history (liver, kidney, heart).\n* Current pregnancy and\u002For lactating.\n* Colonoscopy and\u002For its preparation within 4 weeks of screening.\n* Those who intend to have children during study period.\n* Current probiotic, prebiotics and\u002For metabolic-altering supplement use.\n* Those who are unable to cooperate with investigators and testing.\n* Known history of cancer and\u002For ongoing cancer treatments.\n* Abuse of drugs, alcohol, tobacco, nicotine and other substances.\n* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.\n* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.\n* Type 1 or 2 diabetes mellitus.\n* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.\n* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.\n* Significant weight loss (\\>20%) in prior one month.\n* Conditions affecting safety or outcome integrity.",true,"ALL","40 Years","75 Years",{"count":61,"type":21},80,[24],"This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.",[65,28],"Healthy Aging",[67,68,69,70,71,72,73],"Bifidobacterium adolescentis","iVS-1","Aging","Geroscience","Gut Microbiome","Probiotic","Healthspan","RECRUITING","2026-04-21",{"date":77,"type":39},"2026-04-22",{"date":79,"type":39},"2026-02-01",{"date":81,"type":21},"2027-01",{"name":83,"class":46},"Synbiotic Health",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":57,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)","18 Years",{"count":92,"type":21},118,[24],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[96,97,98,99,100,28,101,102,103],"Rheumatic Arthritis","Rheumatoid Arthritis (RA) Prevention","Inflamation","Antioxidant","Anti Oxidative Stress","C Reactive Protein","Methotrexate","Quality of Life Outcomes","2025-07-21",{"date":106,"type":39},"2025-07-28",{"date":108,"type":21},"2025-08-01",{"date":110,"type":21},"2026-06-01",{"name":112,"class":113},"Ain Shams University","OTHER",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":57,"minAge":90,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100598174","per-safpdos-performance-and-safety-of-polydioxanone-suture-100598174","NCT07068061","PER-SAF_PDOS (Performance and Safety of Polydioxanone Suture)","Evaluation of the Performance and Safety of Polydioxanone Suture (PDO) \"Bio Meyisun\" for the Temporary Correction of the Mid-face Area.","PER-SAF_PDOS","Inclusion Criteria:\n\n* Patients over 18 years old with full legal capacity, male and female;\n* Patients with ability to understand the proposed aesthetic correction and to understand and sign informed consent;\n* Patients who are willing and able to comply with scheduled visits, aesthetic correction procedure and other trial procedures.\n\nExclusion Criteria:\n\n* Pregnant or breast--feeding women;\n* Patients currently participating in any other clinical investigation;\n* Patients who have received a vaccine within 14 days prior to the baseline or plan to have vaccine within 14 days after the injection;\n* Patients with a medical history of systemic diseases, including severe kidney, liver, heart and neurological disorders.",{"count":123,"type":21},50,[24],"This clinical investigation aims to confirm the safety and efficacy of the ID in facial soft tissue reconstruction, specifically for non-incision surgery to tighten and lift the facial skin for a rejuvenated facial appearance.",[127,28,128],"Wrinkles","Face-lift","2025-07-14",{"date":131,"type":39},"2025-07-16",{"date":133,"type":21},"2025-09-01",{"date":135,"type":21},"2026-07-01",{"name":137,"class":46},"21 Century Medical Co., Ltd."]